09:24 EST PTC Therapeutics (PTCT) sees FY25 revenue $600M-$800M
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics sees FY25 revenue $600M-$800M, consensus $963.31M
- PTC Therapeutics sees FY24 revenue ~$814M, consensus $795.38M
- PTC Therapeutics price target lowered to $58 from $63 at RBC Capital
- PTC Therapeutics submits NDA for vatiquinone in Friedreich ataxia
- PTC Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley